Lybalvi™ (olanzapine/samidorphan) – New drug approval
June 1, 2021 - Alkermes announced the FDA approval of Lybalvi (olanzapine/samidorphan), for the treatment of Schizophrenia in adults and Bipolar I disorder in adults: (1) as acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate or (2) maintenance monotherapy treatment.
Top